SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

被引:334
作者
Ye, Yumei [1 ]
Bajaj, Mandeep [2 ]
Yang, Hsiu-Chiung [3 ]
Perez-Polo, Jose R. [1 ]
Birnbaum, Yochai [4 ]
机构
[1] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA
[2] Baylor Coll Med, Dept Med, Endocrinol Sect, Houston, TX 77030 USA
[3] Astrazeneca, CVMD, iMED, Translat Sci, Molndal, Sweden
[4] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA
关键词
Diabetes mellitus; DPP-4; inhibitor; Fibrosis; Inflammation; SGLT-2; COTRANSPORTER; 2; INHIBITORS; REG OUTCOME TRIAL; CARDIOVASCULAR OUTCOMES; SELECTIVE INHIBITOR; HEPATIC STEATOSIS; OXIDATIVE STRESS; RISK; EMPAGLIFLOZIN; PHARMACOKINETICS; HYPERGLYCEMIA;
D O I
10.1007/s10557-017-6725-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We assessed whether (1) dapagliflozin (Dapa, an SGLT2-inhibitor) attenuates the deterioration of heart function Nlrp3 and inflammasome activation in diabetic mice. (2) The effects can be augmented with saxagliptin (Saxa), a DDP4-inhibitor. (3) Dapa effect is possibly SGLT2-independent on cardiofibroblasts in vitro. Type 2 diabetic (BTBR ob/ob) and wild-type (WT) mice received vehicle, Dapa, or Dapa+Saxa for 8 weeks. Glucose tolerance test and echocardiogram were performed. Cardiofibroblasts from WT and BTBR hearts were incubated with Dapa and exposed to LPS. Left ventricular ejection fraction (LVEF) was 81 +/- 1% in the WT and 53 +/- 1% in the T2D-cont mice. Dapa and Dapa+Saxa improved LVEF to 68 +/- 1 and 74.6 +/- 1% in the BTBR mice (p < 0.001). The mRNA levels of NALP3, ASC, IL-1 beta, IL-6, caspase-1, and TNF alpha were significantly higher in the BTBR compared to the WT hearts; and Dapa and Dapa+Saxa significantly attenuated these levels. Likewise, protein levels of NLRP3, TNF alpha, and caspase-1 were higher in the BTBR compared to the WT hearts and Dapa, and to a greater extent Dapa+Saxa, attenuated the increase in the BTBR mice. Collagen-1 and collagen-3 mRNA levels significantly increased in the BTBR mice and these increases were attenuated by Dapa and Dapa+Saxa. P-AMPK/total-AMPK ratio was significantly lower in the BTBR mice than in the WT mice. Dapa and Dapa+Saxa equally increased the ratio in the BTBR mice. This in vitro study showed that NALP3, ASC, IL-1 beta, and caspase-1 mRNA levels were higher in the BTBR cardiofibroblasts and attenuated with Dapa. The effect was AMPK-dependent and SGLT1-independent. Dapa attenuated the activation of the inflammasome, fibrosis, and deterioration of LVEF in BTBR mice. The anti-inflammatory, anti-fibrotic effects are likely SGLT2- and glucose-lowering-independent, as they were replicated in the in vitro model. The effects on remodeling were augmented when Saxa was added to Dapa. Yet, adding Saxa to Dapa did not result in a greater effect on myocardial fibrosis and collagen levels.
引用
收藏
页码:119 / 132
页数:14
相关论文
共 49 条
[31]   Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats [J].
Murase, Hiromichi ;
Kuno, Atsushi ;
Miki, Takayuki ;
Tanno, Masaya ;
Yano, Toshiyuki ;
Kouzu, Hidemichi ;
Ishikawa, Satoko ;
Tobisawa, Toshiyuki ;
Ogasawara, Makoto ;
Nishizawa, Keitaro ;
Miura, Tetsuji .
CARDIOVASCULAR DIABETOLOGY, 2015, 14
[32]   Inflammation and immunity in diabetic vascular complications [J].
Nilsson, Jan ;
Bengtsson, Eva ;
Fredrikson, Gunilla Nordin ;
Bjoerkbacka, Harry .
CURRENT OPINION IN LIPIDOLOGY, 2008, 19 (05) :519-524
[33]   In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans [J].
Obermeier, M. ;
Yao, M. ;
Khanna, A. ;
Koplowitz, B. ;
Zhu, M. ;
Li, W. ;
Komoroski, B. ;
Kasichayanula, S. ;
Discenza, L. ;
Washburn, W. ;
Meng, W. ;
Ellsworth, B. A. ;
Whaley, J. M. ;
Humphreys, W. G. .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (03) :405-414
[34]   MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice [J].
Ohyama, Tatsuya ;
Sato, Ken ;
Yamazaki, Yuichi ;
Hashizume, Hiroaki ;
Horiguchi, Norio ;
Kakizaki, Satoru ;
Mori, Masatomo ;
Kusano, Motoyasu ;
Yamada, Masanobu .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (43) :16227-16235
[35]   Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes [J].
Plosker, Greg L. .
DRUGS, 2014, 74 (18) :2191-2209
[36]   Dapagliflozin for the treatment of type 2 diabetes: a review of the literature [J].
Saeed, Mujahid A. ;
Narendran, Parth .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 :2493-2505
[37]   Effect of dapagliflozin on colon cancer cell [J].
Saito, Tsugumichi ;
Okada, Shuichi ;
Yamada, Eijiro ;
Shimoda, Yoko ;
Osaki, Aya ;
Tagaya, Yuko ;
Shibusawa, Ryo ;
Okada, Junichi ;
Yamada, Masanobu .
ENDOCRINE JOURNAL, 2015, 62 (12) :1133-1137
[38]  
Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9
[39]   Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics [J].
Scheen, A. J. .
DIABETES & METABOLISM, 2016, 42 (04) :224-233
[40]   Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes [J].
Shah, Manasi S. ;
Brownlee, Michael .
CIRCULATION RESEARCH, 2016, 118 (11) :1808-1829